• TG-C US FDA 임상1, 2상 완료
• 서울대 미생물학 학사 ('89) / 카이스트 생명과학 박사 ('95)

• 코오롱인더스트리 미래기술원장 ('18~현재)
• Eastman Chemical Company, Technology Director ('14~'17)
• BS-Material Science & Engineering and Nuclear Engineering, University of California, Berkeley, CA
• PhD-Nuclear Engineering, University of California, Berkeley, CA

• Kolon TissueGene, Inc. CFO ('17~현재)
• (주)코오롱 경영관리실 상무 ('04~'17)
• (주)대우 국제금융부 ('93~'00)
• 고려대 경제학 학사 ('92)

• Kolon TissueGene, Inc.('21~현재)
• ㈜ 코오롱 경영관리실('13~'21)
• 국민대학교 수학과 학사('02)

• Kolon TissueGene, Inc., Chief Medical Officer (’21 ~ 현재)
• Platbio Inc. 대표이사 ('18 ~ 현재)
• Executive Vice President, Hanmi Pharm Co., Ltd ('17~'18)
• Seoul National University College of Medicine, Seoul, MD
• Seoul National University Graduate School, Seoul, PHD, Medical Science

Diana M. Halim joined Kolon TissueGene, Inc. in January 2020 as Senior Director of Regulatory Affairs and shortly thereafter became Vice President of Clinical and Regulatory Affairs. She previously served as the Director of Regulatory Affairs at RRD International, LLC, Sucampo Pharmaceuticals, Inc., and AnGes, Inc. She received her B.A. degree in English/Biology from George Washington University, Washington, DC and her M.S. degree in Biotechnology from Johns Hopkins University, Baltimore, MD.